Meeting
2015 ASCO Annual Meeting
A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
Authors
Dirk Schadendorf
University Hospital Essen, Essen, Germany
Dirk Schadendorf , Paolo Antonio Ascierto , Enrique Espinosa , John B. A. G. Haanen , Frank Hermann , Paul D. Nathan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT02156804
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS9083)
DOI
10.1200/jco.2015.33.15_suppl.tps9083
Abstract #
TPS9083
Poster Bd #
324a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): a single-arm, open-label, multicenter, phase II study (CheckMate 172).
First Author: Paolo Antonio Ascierto
Poster
2013 ASCO Annual Meeting
An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
First Author: F. Stephen Hodi
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial.
First Author: Alberto Fusi
Poster
2015 ASCO Annual Meeting
A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain.
First Author: Kim Allyson Margolin